SEC Company Response from Verrica Pharmaceuticals Inc. (VRCA) (CIK 0001660334) (VRCA) — Mar 23, 2020
Verrica Pharmaceuticals Inc. (VRCA) (CIK 0001660334)
Date: March 23, 2020 · CIK: 0001660334 · Accession: 0001193125-20-082429
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-237171
Letter
Re: Verrica Pharmaceuticals Inc. (the “Company”)
March 23, 2020
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Ada Sarmento
Registration Statement on Form S-3
Filed: March 13, 2020
File No. 333-237171
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement to become effective at 4:30 p.m. Eastern Time on March 25, 2020 or as soon thereafter as is practicable, or at such later time as the Registrant may orally request via telephone call to the staff. The Registrant hereby authorizes each of Darren DeStefano, Mark Ballantyne and Jason Drory of Cooley LLP to make such request on its behalf.
Once the above-referenced Registration Statement has been declared effective, please orally confirm that event with Darren DeStefano of Cooley LLP at (703) 456-8034, or in his absence, Mark Ballantyne of Cooley LLP at (703) 456-8084.
Very truly yours,
Verrica Pharmaceuticals Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP March 23, 2020 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Ada Sarmento Re: Verrica Pharmaceuticals Inc. (the “Company”) Registration Statement on Form S-3 Filed: March 13, 2020 File No. 333-237171 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement to become effective at 4:30 p.m. Eastern Time on March 25, 2020 or as soon thereafter as is practicable, or at such later time as the Registrant may orally request via telephone call to the staff. The Registrant hereby authorizes each of Darren DeStefano, Mark Ballantyne and Jason Drory of Cooley LLP to make such request on its behalf. Once the above-referenced Registration Statement has been declared effective, please orally confirm that event with Darren DeStefano of Cooley LLP at (703) 456-8034, or in his absence, Mark Ballantyne of Cooley LLP at (703) 456-8084. Very truly yours, Verrica Pharmaceuticals Inc. By: /s/ A. Brian Davis A. Brian Davis Chief Financial Officer